Viatris (VTRS) Share-based Compensation (2020 - 2026)
Viatris (VTRS) posted Share-based Compensation of $30.4 million for Q2 2026, down 46.19% on a QoQ basis from $56.5 million in Q1 2026, and down 18.06% year-over-year from $37.1 million in Q2 2025.
Analysis
Viatris (VTRS) Share-based Compensation (2020 - 2026) Analysis & Trends
Viatris has reported Share-based Compensation for 7 years, with the latest figure at $30.4 million in Q2 2026.
- On a quarterly basis, Share-based Compensation fell 18.06% year-over-year to $30.4 million in Q2 2026; TTM through Jun 2026 was $172.3 million, a 9.75% increase from a year earlier, with the FY2025 full-year figure at $177.7 million, up 21.63% from the prior year.
- Share-based Compensation was $30.4 million for Q2 2026 at Viatris, down from $56.5 million in the prior quarter.
- The five-year high for Share-based Compensation was $56.5 million in Q1 2026, with the low at $28.3 million in Q1 2022.
- Average Share-based Compensation over 5 years is $39.3 million, with a median of $36.6 million recorded in 2025.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation jumped 88.51% in 2023, then tumbled 42.11% in 2024.
- Over 5 years, Share-based Compensation stood at $29.6 million in 2022, then surged by 88.51% to $55.8 million in 2023, then slumped by 42.11% to $32.3 million in 2024, then jumped by 52.94% to $49.4 million in 2025, then plunged by 38.46% to $30.4 million in 2026.
- The last three Share-based Compensation figures came in at $30.4 million (Q2 2026), $56.5 million (Q1 2026), and $49.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 40.00 Mn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 30.40 Mn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 1.02 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 176,000.00 |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 54.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 2.92 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 11.41 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 29.30 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 7.04 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 30.40 Mn |
| Mar 31, 2026 | 56.50 Mn |
| Dec 31, 2025 | 49.40 Mn |
| Sep 30, 2025 | 36.00 Mn |
| Jun 30, 2025 | 37.10 Mn |
| Mar 31, 2025 | 55.20 Mn |
| Dec 31, 2024 | 32.30 Mn |
| Sep 30, 2024 | 32.40 Mn |
| Jun 30, 2024 | 34.70 Mn |
| Mar 31, 2024 | 46.70 Mn |
| Dec 31, 2023 | 55.80 Mn |
| Sep 30, 2023 | 43.10 Mn |
| Jun 30, 2023 | 39.20 Mn |
| Mar 31, 2023 | 42.60 Mn |
| Dec 31, 2022 | 29.60 Mn |
| Sep 30, 2022 | 29.10 Mn |
| Jun 30, 2022 | 29.40 Mn |
| Mar 31, 2022 | 28.30 Mn |
| Dec 31, 2021 | 22.50 Mn |
| Sep 30, 2021 | 25.00 Mn |